The Moving Target: Cis-Mutation-Driven Resistance to p53-Y220C Reactivator.

Abstract excerpt

The study by Fece de la Cruz, Varkaris, and colleagues uncovered a critical mechanism underlying resistance to the p53-Y220C reactivator rezatapopt in the PYNNACLE clinical trial. Specifically, rezatapopt treatment was shown to select for secondary mutations in the TP53 gene on the Y220C-mutant background, thereby abrogating its therapeutic efficacy. See related article by Fece de la Cruz et al., p. 677.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Resistance, Neoplasm
• Share to TP53 gene
• Share to Mutation